Although Duchenne muscular dystrophy (DMD) is not an ideal program for newborn screening, the ethical reservations about instituting a program can be overcome. A newborn screening for the disease has the potential to improve the lives of many patients in the near future, and done right, it would create an infrastructure that could revolutionize care. Newborn screening will allow patients to receive treatments earlier, and it may allow them to delay the onset of symptoms. In time, access to presymptomatic patients may allow researchers to find a cure.